Jeffery D. Molkentin
 | A major contributor to this article appears to have a close connection with its subject. (January 2021) |
Jeffery Daniel Molkentin (born January 15, 1967 in Milwaukee, Wisconsin) is an American molecular biologist.[1] He is the director of Molecular Cardiovascular Biology for Cincinnati Children's hospital where he is also co-director of their Heart Institute.[2] Molkentin holds a professorship at the University of Cincinnati's Department of Pediatrics.[3][4]
Biography[]
Molkentin was born and raised in Milwaukee, Wisconsin.[1], where he attended Marquette University, receiving a B.S. in biology in 1989. He began studies to be a medical doctor at the University of Wisconsin,[2] but switched to a research program, and received his PhD in physiology from the Medical College of Wisconsin in 1994.[1]
Molkentin's work focuses on heart disease and muscular dystrophy, though he is involved in other types of research entailing calcium handling, ER stress signaling, cardiac hypertrophic signaling pathways,[5] and COVID-19 disease mechanisms.[6] One of Molkentin's most notable research achievements was his contribution to stem cell therapy in the heart and his disproving prior research about the topic.[7][8]
Molkentin is among the most highly cited researchers in the world, with his publications being cited over 50,000 times in literature.[9] His work has been published in several prestigious research journals, including "Nature",[10] "PNAS",[11] and "Circulation Research".[12]
Molkentin has been a full investigator for the Howard Hughes Medical Institute (HHMI) from 2008-2021.[13]
Awards and honors[]
- 1998 Pew Scholar in the Biomedical Sciences[14]
- 2012 AHA Basic Science Research Prize[15]
- 2015 Lucian Award[15]
- 2019 AHA Merit Award Winner[16][17]
Selected publications[]
 | This section's use of external links may not follow Wikipedia's policies or guidelines. (January 2021) |
- MCUb induction protects the heart from postischemic remodeling. Huo, J; Lu, S; Kwong, JQ; Bround, MJ; Grimes, KM; Sargent, MA; Brown, ME; Davis, ME; Bers, DM; Molkentin, JD. Circulation Research. 2020; 127:379-390.
- An acute immune response underlies the benefit of cardiac stem cell therapy. Vagnozzi, RJ; Maillet, M; Sargent, MA; Khalil, H; Johansen, AK Z; Schwanekamp, JA; York, AJ; Huang, V; Nahrendorf, M; Sadayappan, S; et al. Nature. 2020; 577:405-409.
- Disruption of valosin-containing protein activity causes cardiomyopathy and reveals pleiotropic functions in cardiac homeostasis. Brody, MJ; Vanhoutte, D; Bakshi, CV; Liu, R; Correll, RN; Sargent, MA; Molkentin, JD. The Journal of biological chemistry. 2019; 294:8918-8929.
- ERK1/2 signaling induces skeletal muscle slow fiber-type switching and reduces muscular dystrophy disease severity. Boyer, JG; Prasad, V; Song, T; Lee, D; Fu, X; Grimes, KM; Sargent, MA; Sadayappan, S; Molkentin, JD. JCI insight. 2019; 5.
References[]
- ^ a b c "Jeffery D. Molkentin | Science History Institute | Center for Oral History". oh.sciencehistory.org. Retrieved 2021-01-03.
- ^ a b "Jeffery D. Molkentin biography and affiliation".
{{cite web}}: CS1 maint: url-status (link) - ^ "Cancer Biology Directory | Molgen | UC Cincinnati College of Medicine". Default. Retrieved 2021-01-02.
- ^ "Jeffery Molkentin, PhD | Jain Foundation". www.jain-foundation.org. Retrieved 2021-01-03.
- ^ "Regulation of Cardiac Hypertrophy | Molkentin Lab". www.cincinnatichildrens.org. Retrieved 2021-01-03.
- ^ "Cincinnati Children's launches six Covid-specific research projects". www.bizjournals.com. Retrieved 2021-01-03.
- ^ Huynh, Karina (February 2020). "Stem cell therapy improves heart function by triggering an acute immune response". Nature Reviews Cardiology. 17 (2): 69. doi:10.1038/s41569-019-0327-6. ISSN 1759-5010. PMID 31827260.
- ^ Johnson, Carolyn Y. "Benefits of stem cell heart therapy may have nothing to do with stem cells, a study on mice suggests". Washington Post. ISSN 0190-8286. Retrieved 2021-01-03.
- ^ "Jeffery D Molkentin". scholar.google.com. Retrieved 2021-01-02.
- ^ Cyranoski, David (2019-11-27). "Stem-cell therapies use immune system to repair broken hearts". Nature. doi:10.1038/d41586-019-03645-7. PMID 33239769.
- ^ Karch, J.; Molkentin, J. D. (2014-07-07). "Identifying the components of the elusive mitochondrial permeability transition pore". Proceedings of the National Academy of Sciences. 111 (29): 10396–10397. Bibcode:2014PNAS..11110396K. doi:10.1073/pnas.1410104111. ISSN 0027-8424. PMC 4115577. PMID 25002521.
- ^ Williams Ruth (2014-01-17). "Jeffery Molkentin". Circulation Research. 114 (2): 239–241. doi:10.1161/CIRCRESAHA.113.303225. PMID 24436426.
- ^ "Jeffery D. Molkentin". HHMI.org. Retrieved 2021-01-02.
- ^ "Jeffery D. Molkentin, Ph.D." miRagen Therapeutics, Inc. Retrieved 2021-01-03.
- ^ a b Ince Susan (2015-08-28). "2015 Lucian Award". Circulation Research. 117 (6): 498–501. doi:10.1161/CIRCRESAHA.115.307326. PMID 26316606.
- ^ "Cincinnati Children's scientist lands $1M for 'revolutionary' heart research". www.bizjournals.com. Retrieved 2021-01-03.
{{cite web}}: CS1 maint: url-status (link) - ^ "Jeffery D. Molkentin Ph.D." American Heart Association. Retrieved 2021-01-03.
Authority control  | |
|---|---|
| General |
|
| Scientific databases | |
- 1967 births
- University of Cincinnati people
- Molecular biologists
- Marquette University alumni
- Living people